GLP-3 R Phase 2: −28.7%143 Compounds · 5 Layers>98% HPLC All VialsFree Shipping $200+Third-Party Test ReportsResearch Use OnlyCAS Numbers VerifiedGHK-Cu: 4,000+ GenesGLP-3 R Phase 2: −28.7%143 Compounds · 5 Layers>98% HPLC All VialsFree Shipping $200+Third-Party Test ReportsResearch Use OnlyCAS Numbers VerifiedGHK-Cu: 4,000+ Genes
IPA/TESA Blend 15mg

IPA/TESA Blend 15mg

Ipamorelin + Tesamorelin

CAS: 170851-70-4 / 218949-48-5

$134.99$149.9910% OFFIn Stock

Ipamorelin 5mg + Tesamorelin 10mg in a single vial. Combines GHSR1a pulse-frequency enhancement (Ipamorelin) with FDA-validated GHRH receptor agonism for visceral fat reduction (Tesamorelin). 99.0% HPLC purity.

Specifications

Ipamorelin5mg
Tesamorelin10mg
FormLyophilized Powder
Purity99.0% HPLC
Storage-20C long-term
Shop This Compound

For laboratory research use only. Not for human consumption.

Mechanism of Action

Tesamorelin drives GHRH receptor-mediated GH release with clinical VAT reduction data. Ipamorelin adds GHS-R1a frequency modulation for a broader GH pulse profile.

Research FAQ

Why pair Ipamorelin with Tesamorelin specifically?

Tesamorelin covers GHRH receptor amplitude. Ipamorelin covers ghrelin receptor frequency. The combination provides dual-axis GH stimulation with the added benefit of Tesamorelin clinical VAT data.

Related Compounds